Author information from the last article
Lise Sofie Haug Nissen-Meyer er spesialist i immunologi og transfusjonsmedisin, førsteamanuensis ved Institutt for klinisk medisin, Universitetet i Oslo og seksjonsleder ved Seksjon for blodgivning, Avdeling for immunologi og transfusjonsmedisin, Oslo universitetssykehus.
Articles by Lise Sofie Haug Nissen-Meyer
Is Norway's transfusion service ethical and sustainable?
- Morten Haugen,
- Hans Erik Heier,
- Lise Sofie Haug Nissen-Meyer
02.02.2026:
The use of immunoglobulins is increasing, but their administration is often not supported by robust scientific evidence. This creates ethical and supply-related challenges that require coordinated action at a national level. Immunoglobulins are used both as replacement therapy for immunodeficiency...
Convalescent plasma from Norwegian blood donors to treat COVID-19
- Lise Sofie Haug Nissen-Meyer,
- Tine Torsvik Steinsvåg,
- Mona Høysæter Fenstad,
- Ingvild Hausberg Sørvoll,
- Marte Hvalryg,
- Thomas Larsen Titze,
- Karin Magnussen,
- Gunn Kristoffersen,
- Kathrine Margrethe Neuman Johnsen,
- Abid Hussain Llohn,
- Brita Hermundstad,
- Lilja Synnøve Høiback,
- Morten Haugen,
- Einar K. Kristoffersen,
- Line Boulland,
- Anne-Marte Bakken Kran,
- Fridtjof Lund-Johansen,
- John Torgils Vaage,
- Øystein Flesland,
- Tor Audun Hervig
03.08.2023:
Convalescent plasma for the treatment of COVID-19 is a blood component from a donor who has recovered from COVID-19. Despite uncertainty about its efficacy, many countries, including Norway, initiated the collection and use of COVID-19 convalescent plasma. The set-up and background of the Norwegian...
COVID-19 patients treated with convalescent plasma
- Lise Sofie Haug Nissen-Meyer,
- Magnhild Eide Macpherson,
- Linda Gail Skeie,
- Marte Hvalryg,
- Abid Hussain Llohn,
- Tine Torsvik Steinsvåg,
- Mona Høysæter Fenstad,
- Anders Tveita,
- Einar K. Kristoffersen,
- Tatjana Sundic,
- Fridtjof Lund-Johansen,
- John Torgils Vaage,
- Øystein Flesland,
- Anne Ma Dyrhol-Riise,
- Jan Cato Holter,
- Tor Audun Hervig,
- Børre Fevang
03.08.2023:
COVID-19 convalescent plasma (NORPLASMA) (1) first became available to Norwegian patients in the spring of 2020. The Norwegian Directorate of Health recommended use of the product in patients who were at risk of developing a severe/life-threatening course of COVID-19, where the attending doctor...
COVID-19 convalescent plasma from Norwegian blood donors
- Lise Sofie Haug Nissen-Meyer,
- Tor Hervig,
- Børre Fevang,
- Gunnstein Norheim,
- Anne-Marte Bakken Kran,
- John Torgils Vaage,
- Øystein Flesland
14.06.2022:
The collection and use of convalescent plasma to treat COVID-19 has taught us important lessons about the organisation, testing and selection of blood donors and patients. This is knowledge that can be used in the next pandemic. Convalescent plasma is plasma taken from survivors of a severe...
Paroxysmal nocturnal haemoglobinuria at Oslo University Hospital 2000–2010
- Lise Sofie Haug Nissen-Meyer,
- Geir E. Tjønnfjord,
- Elzbieta Golebiowska,
- Jens Kjeldsen-Kragh,
- Çiğdem Akalin Akkök
16.06.2015:
The rare disease paroxysmal nocturnal haemoglobinuria (PNH) has an estimated incidence of 1.3 cases per million population per year (1). Patients are classified as either classic PNH (without other bone marrow disease), secondary PNH (associated with bone marrow diseases such as aplastic anaemia and...